Combined plasma biomarkers for diagnosing mild cognition impairment and Alzheimer's disease

Ming Jang Chiu, Shieh Yueh Yang, Herng Er Horng, Che Chuan Yang, Ta Fu Chen, Jen Je Chieh, Hsin Hsien Chen, Ting Chi Chen, Chia Shin Ho, Shuo Fen Chang, Hao Chun Liu, Chin Yih Hong, Hong Chang Yang

Research output: Contribution to journalArticle

57 Citations (Scopus)

Abstract

A highly sensitive immunoassay, the immunomagnetic reduction, is used to measure several biomarkers for plasma that is related to Alzheimer's disease (AD). These biomarkers include Aβ-40, Aβ-42, and tau proteins. The samples are composed of four groups: healthy controls (n = 66), mild cognitive impairment (MCI, n = 22), very mild dementia (n = 23), and mild-to-serve dementia, all due to AD (n = 22). It is found that the concentrations of both Aβ-42 and tau protein for the healthy controls are significantly lower than those of all of the other groups. The sensitivity and the specificity of plasma Aβ-42 and tau protein in differentiating MCI from AD are all around 0.9 (0.88-0.97). However, neither plasma Aβ-42 nor tau-protein concentration is an adequate parameter to distinguish MCI from AD. A parameter is proposed, which is the product of plasma Aβ-42 and tau-protein levels, to differentiate MCI from AD. The sensitivity and specificity are found to be 0.80 and 0.82, respectively. It is concluded that the use of combined plasma biomarkers not only allows the differentiation of the healthy controls and patients with AD in both the prodromal phase and the dementia phase, but it also allows AD in the prodromal phase to be distinguished from that in the dementia phase.

Original languageEnglish
Pages (from-to)1530-1536
Number of pages7
JournalACS Chemical Neuroscience
Volume4
Issue number12
DOIs
Publication statusPublished - 2013 Dec 18

Fingerprint

Biomarkers
Cognition
tau Proteins
Alzheimer Disease
Plasmas
Dementia
Sensitivity and Specificity
Immunoassay
Control Groups

Keywords

  • Alzheimer's disease
  • Immunomagnetic reduction
  • biomarkers
  • mild cognition impairment
  • plasma

ASJC Scopus subject areas

  • Biochemistry
  • Physiology
  • Cognitive Neuroscience
  • Cell Biology

Cite this

Combined plasma biomarkers for diagnosing mild cognition impairment and Alzheimer's disease. / Chiu, Ming Jang; Yang, Shieh Yueh; Horng, Herng Er; Yang, Che Chuan; Chen, Ta Fu; Chieh, Jen Je; Chen, Hsin Hsien; Chen, Ting Chi; Ho, Chia Shin; Chang, Shuo Fen; Liu, Hao Chun; Hong, Chin Yih; Yang, Hong Chang.

In: ACS Chemical Neuroscience, Vol. 4, No. 12, 18.12.2013, p. 1530-1536.

Research output: Contribution to journalArticle

Chiu, MJ, Yang, SY, Horng, HE, Yang, CC, Chen, TF, Chieh, JJ, Chen, HH, Chen, TC, Ho, CS, Chang, SF, Liu, HC, Hong, CY & Yang, HC 2013, 'Combined plasma biomarkers for diagnosing mild cognition impairment and Alzheimer's disease', ACS Chemical Neuroscience, vol. 4, no. 12, pp. 1530-1536. https://doi.org/10.1021/cn400129p
Chiu, Ming Jang ; Yang, Shieh Yueh ; Horng, Herng Er ; Yang, Che Chuan ; Chen, Ta Fu ; Chieh, Jen Je ; Chen, Hsin Hsien ; Chen, Ting Chi ; Ho, Chia Shin ; Chang, Shuo Fen ; Liu, Hao Chun ; Hong, Chin Yih ; Yang, Hong Chang. / Combined plasma biomarkers for diagnosing mild cognition impairment and Alzheimer's disease. In: ACS Chemical Neuroscience. 2013 ; Vol. 4, No. 12. pp. 1530-1536.
@article{fbc1d2d1fab44989a60ebe95a2f9142c,
title = "Combined plasma biomarkers for diagnosing mild cognition impairment and Alzheimer's disease",
abstract = "A highly sensitive immunoassay, the immunomagnetic reduction, is used to measure several biomarkers for plasma that is related to Alzheimer's disease (AD). These biomarkers include Aβ-40, Aβ-42, and tau proteins. The samples are composed of four groups: healthy controls (n = 66), mild cognitive impairment (MCI, n = 22), very mild dementia (n = 23), and mild-to-serve dementia, all due to AD (n = 22). It is found that the concentrations of both Aβ-42 and tau protein for the healthy controls are significantly lower than those of all of the other groups. The sensitivity and the specificity of plasma Aβ-42 and tau protein in differentiating MCI from AD are all around 0.9 (0.88-0.97). However, neither plasma Aβ-42 nor tau-protein concentration is an adequate parameter to distinguish MCI from AD. A parameter is proposed, which is the product of plasma Aβ-42 and tau-protein levels, to differentiate MCI from AD. The sensitivity and specificity are found to be 0.80 and 0.82, respectively. It is concluded that the use of combined plasma biomarkers not only allows the differentiation of the healthy controls and patients with AD in both the prodromal phase and the dementia phase, but it also allows AD in the prodromal phase to be distinguished from that in the dementia phase.",
keywords = "Alzheimer's disease, Immunomagnetic reduction, biomarkers, mild cognition impairment, plasma",
author = "Chiu, {Ming Jang} and Yang, {Shieh Yueh} and Horng, {Herng Er} and Yang, {Che Chuan} and Chen, {Ta Fu} and Chieh, {Jen Je} and Chen, {Hsin Hsien} and Chen, {Ting Chi} and Ho, {Chia Shin} and Chang, {Shuo Fen} and Liu, {Hao Chun} and Hong, {Chin Yih} and Yang, {Hong Chang}",
year = "2013",
month = "12",
day = "18",
doi = "10.1021/cn400129p",
language = "English",
volume = "4",
pages = "1530--1536",
journal = "ACS Chemical Neuroscience",
issn = "1948-7193",
publisher = "American Chemical Society",
number = "12",

}

TY - JOUR

T1 - Combined plasma biomarkers for diagnosing mild cognition impairment and Alzheimer's disease

AU - Chiu, Ming Jang

AU - Yang, Shieh Yueh

AU - Horng, Herng Er

AU - Yang, Che Chuan

AU - Chen, Ta Fu

AU - Chieh, Jen Je

AU - Chen, Hsin Hsien

AU - Chen, Ting Chi

AU - Ho, Chia Shin

AU - Chang, Shuo Fen

AU - Liu, Hao Chun

AU - Hong, Chin Yih

AU - Yang, Hong Chang

PY - 2013/12/18

Y1 - 2013/12/18

N2 - A highly sensitive immunoassay, the immunomagnetic reduction, is used to measure several biomarkers for plasma that is related to Alzheimer's disease (AD). These biomarkers include Aβ-40, Aβ-42, and tau proteins. The samples are composed of four groups: healthy controls (n = 66), mild cognitive impairment (MCI, n = 22), very mild dementia (n = 23), and mild-to-serve dementia, all due to AD (n = 22). It is found that the concentrations of both Aβ-42 and tau protein for the healthy controls are significantly lower than those of all of the other groups. The sensitivity and the specificity of plasma Aβ-42 and tau protein in differentiating MCI from AD are all around 0.9 (0.88-0.97). However, neither plasma Aβ-42 nor tau-protein concentration is an adequate parameter to distinguish MCI from AD. A parameter is proposed, which is the product of plasma Aβ-42 and tau-protein levels, to differentiate MCI from AD. The sensitivity and specificity are found to be 0.80 and 0.82, respectively. It is concluded that the use of combined plasma biomarkers not only allows the differentiation of the healthy controls and patients with AD in both the prodromal phase and the dementia phase, but it also allows AD in the prodromal phase to be distinguished from that in the dementia phase.

AB - A highly sensitive immunoassay, the immunomagnetic reduction, is used to measure several biomarkers for plasma that is related to Alzheimer's disease (AD). These biomarkers include Aβ-40, Aβ-42, and tau proteins. The samples are composed of four groups: healthy controls (n = 66), mild cognitive impairment (MCI, n = 22), very mild dementia (n = 23), and mild-to-serve dementia, all due to AD (n = 22). It is found that the concentrations of both Aβ-42 and tau protein for the healthy controls are significantly lower than those of all of the other groups. The sensitivity and the specificity of plasma Aβ-42 and tau protein in differentiating MCI from AD are all around 0.9 (0.88-0.97). However, neither plasma Aβ-42 nor tau-protein concentration is an adequate parameter to distinguish MCI from AD. A parameter is proposed, which is the product of plasma Aβ-42 and tau-protein levels, to differentiate MCI from AD. The sensitivity and specificity are found to be 0.80 and 0.82, respectively. It is concluded that the use of combined plasma biomarkers not only allows the differentiation of the healthy controls and patients with AD in both the prodromal phase and the dementia phase, but it also allows AD in the prodromal phase to be distinguished from that in the dementia phase.

KW - Alzheimer's disease

KW - Immunomagnetic reduction

KW - biomarkers

KW - mild cognition impairment

KW - plasma

UR - http://www.scopus.com/inward/record.url?scp=84890589183&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84890589183&partnerID=8YFLogxK

U2 - 10.1021/cn400129p

DO - 10.1021/cn400129p

M3 - Article

C2 - 24090201

AN - SCOPUS:84890589183

VL - 4

SP - 1530

EP - 1536

JO - ACS Chemical Neuroscience

JF - ACS Chemical Neuroscience

SN - 1948-7193

IS - 12

ER -